MAXCYTE, INC.MXCTEarnings & Financial Report
Nasdaq · Industrials · Services-Commercial Physical & Biological Research
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9.90% | 10.4M | flat | 2024-11-08 |
| Cadian Capital Management, LP | 7.80% | 8.2M | ▲ +2.30pp | 2024-11-13 |
| The Vanguard Group | 5.09% | 5.3M | — | 2024-02-13 |
| Integrated Core Strategies | 4.00% | 4.2M | ▼ -1.50pp | 2024-10-31 |
| Casdin Capital, LLC | 0.00% | 57.8K | — | 2024-02-14 |
Insider Transactions
Net 90d: −$8.3K · buys $0 / sells $8.3KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-15 | Parmeet Ahuja | Chief Financial Officer | Grant | 187.5K | $0.00 | $0 |
| 2026-03-27 | Maher Masoud | President and CEO | Grant | 300.0K | $0.00 | $0 |
| 2026-03-17 | Swirsky Douglas J | CHIEF FINANCIAL OFFICER | Sell (open market) | 10.1K | $0.81 | $8.3K |
1–3 of 3